{"transactions":[{"id":833452,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T22:00:39.000Z","date":"2026-03-18","kind":"sale","planned":false,"acquired":false,"shares":37,"price":32.85,"value":1215.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."}],"balance_after":10172,"source":{"system":"sec-edgar","filing":"0001774690-26-000006","document":"form4-03192026_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000006/form4-03192026_100335.xml","form_type":"4"}},{"id":833451,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T22:00:39.000Z","date":"2026-03-18","kind":"sale","planned":false,"acquired":false,"shares":172,"price":31.7888,"value":5467.6736,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive."}],"balance_after":10209,"source":{"system":"sec-edgar","filing":"0001774690-26-000006","document":"form4-03192026_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000006/form4-03192026_100335.xml","form_type":"4"}},{"id":833450,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T22:00:39.000Z","date":"2026-03-18","kind":"sale","planned":false,"acquired":false,"shares":2173,"price":31.2838,"value":67979.6974,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive."}],"balance_after":10381,"source":{"system":"sec-edgar","filing":"0001774690-26-000006","document":"form4-03192026_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000006/form4-03192026_100335.xml","form_type":"4"}},{"id":833449,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T22:00:39.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":922,"price":33.3754,"value":30772.1188,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive."}],"balance_after":12554,"source":{"system":"sec-edgar","filing":"0001774690-26-000006","document":"form4-03192026_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000006/form4-03192026_100335.xml","form_type":"4"}},{"id":833448,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T22:00:39.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":1274,"price":32.7394,"value":41709.9956,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4."}],"balance_after":13476,"source":{"system":"sec-edgar","filing":"0001774690-26-000006","document":"form4-03192026_100335.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000006/form4-03192026_100335.xml","form_type":"4"}},{"id":837855,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T21:26:02.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date."}],"balance_after":44250,"derivative":{"expiration_date":"2029-03-15","underlying":"Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001774690-26-000004","document":"form4-03172026_090359.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000004/form4-03172026_090359.xml","form_type":"4"}},{"id":837854,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-17T21:26:02.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14750,"source":{"system":"sec-edgar","filing":"0001774690-26-000004","document":"form4-03172026_090359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000004/form4-03172026_090359.xml","form_type":"4"}},{"id":893331,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-19T21:22:34.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the issuer's common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date."}],"balance_after":40000,"derivative":{"expiration_date":"2030-02-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001774690-26-000002","document":"form4-02192026_090230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000002/form4-02192026_090230.xml","form_type":"4"}},{"id":893330,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-19T21:22:34.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date."}],"balance_after":60000,"derivative":{"exercise_price":31.09,"expiration_date":"2036-02-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001774690-26-000002","document":"form4-02192026_090230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000177469026000002/form4-02192026_090230.xml","form_type":"4"}},{"id":1195684,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-20T22:17:01.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The award vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date."}],"balance_after":59000,"derivative":{"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001415889-25-008713","document":"form4-03202025_100358.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000141588925008713/form4-03202025_100358.xml","form_type":"4"}},{"id":1195683,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-03-20T22:17:01.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":89000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date."}],"balance_after":89000,"derivative":{"exercise_price":8.33,"expiration_date":"2035-03-19","underlying":"Common Stock","underlying_shares":89000},"source":{"system":"sec-edgar","filing":"0001415889-25-008713","document":"form4-03202025_100358.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000141588925008713/form4-03202025_100358.xml","form_type":"4"}},{"id":1511315,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T20:14:20.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":396200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/4 of the total award on May 7, 2025, and as to 1/48 of the total award monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date."}],"balance_after":396200,"derivative":{"exercise_price":14.13,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":396200},"source":{"system":"sec-edgar","filing":"0001415889-24-013477","document":"form4-05172024_080515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623526/000141588924013477/form4-05172024_080515.xml","form_type":"4"}},{"id":2846340,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-19T23:47:29.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":75000,"derivative":{"exercise_price":28.69,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-21-007433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321007433/doc4.xml","form_type":"4"}},{"id":2911055,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-11T22:59:09.000Z","date":"2021-01-08","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":218171,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-21-001378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321001378/doc4.xml","form_type":"4"}},{"id":2911054,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-11T22:59:09.000Z","date":"2021-01-08","kind":"sale","acquired":false,"shares":3000,"price":33.94,"value":101820.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $34.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-001378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321001378/doc4.xml","form_type":"4"}},{"id":2911053,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-11T22:59:09.000Z","date":"2021-01-08","kind":"exercise","acquired":true,"shares":3000,"price":10.86,"value":32580.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-21-001378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321001378/doc4.xml","form_type":"4"}},{"id":2950193,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-10T21:16:59.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":221171,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-033341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320033341/doc4.xml","form_type":"4"}},{"id":2950192,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-10T21:16:59.000Z","date":"2020-12-08","kind":"sale","acquired":false,"shares":1941,"price":34.0514,"value":66093.7674,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-033341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320033341/doc4.xml","form_type":"4"}},{"id":2950191,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-10T21:16:59.000Z","date":"2020-12-08","kind":"sale","acquired":false,"shares":1059,"price":33.2701,"value":35233.0359,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.72 to $33.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1941,"source":{"system":"sec-edgar","filing":"0000899243-20-033341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320033341/doc4.xml","form_type":"4"}},{"id":2950190,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-12-10T21:16:59.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":3000,"price":10.86,"value":32580.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-033341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320033341/doc4.xml","form_type":"4"}},{"id":2983837,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-12T22:00:11.000Z","date":"2020-11-09","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":224171,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-030831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030831/doc4.xml","form_type":"4"}},{"id":2983836,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-12T22:00:11.000Z","date":"2020-11-09","kind":"sale","acquired":false,"shares":3000,"price":32.9639,"value":98891.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.65 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-030831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030831/doc4.xml","form_type":"4"}},{"id":2983835,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-12T22:00:11.000Z","date":"2020-11-09","kind":"exercise","acquired":true,"shares":3000,"price":10.86,"value":32580.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-030831","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030831/doc4.xml","form_type":"4"}},{"id":3009409,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-09T20:12:22.000Z","date":"2020-10-08","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":227171,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-027904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320027904/doc4.xml","form_type":"4"}},{"id":3009408,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-10-09T20:12:22.000Z","date":"2020-10-08","kind":"sale","acquired":false,"shares":3000,"price":33.5253,"value":100575.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-027904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320027904/doc4.xml","form_type":"4"}},{"id":3009407,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-10-09T20:12:22.000Z","date":"2020-10-08","kind":"exercise","acquired":true,"shares":3000,"price":10.86,"value":32580.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-027904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320027904/doc4.xml","form_type":"4"}},{"id":3030332,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-16T22:09:51.000Z","date":"2020-09-14","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":230171,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-025360","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320025360/doc4.xml","form_type":"4"}},{"id":3030331,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-16T22:09:51.000Z","date":"2020-09-14","kind":"sale","acquired":false,"shares":3000,"price":31,"value":93000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-025360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320025360/doc4.xml","form_type":"4"}},{"id":3030330,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-16T22:09:51.000Z","date":"2020-09-14","kind":"exercise","acquired":true,"shares":3000,"price":10.86,"value":32580.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0000899243-20-025360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320025360/doc4.xml","form_type":"4"}},{"id":3296755,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":57125,"kind":"person","name":"Leggett Thomas","position":1,"cik":"0001774690","reported_name":"Leggett Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-31T21:55:22.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":55540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":55540,"derivative":{"exercise_price":19,"expiration_date":"2030-01-29","underlying":"Common Stock","underlying_shares":55540},"source":{"system":"sec-edgar","filing":"0000899243-20-002446","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320002446/doc4.xml","form_type":"4"}}]}